Navigation Links
Kensey Nash to Participate in the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum Conference
Date:3/13/2009

EXTON, Pa., March 13 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) is scheduled to present at the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum at The Grand Hyatt in New York City on Tuesday, March 24, 2009.

Joseph W. Kaufmann, Kensey Nash's CEO, will deliver the Company's presentation, beginning at approximately 11:35 a.m. (ET). The presentation materials will be available on the company's website (www.kenseynash.com) beginning at 11:35 a.m. (ET) on Tuesday, March 24, 2009.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Kensey Nash Announces Appointment of Chief Financial Officer
2. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
3. Kensey Nash Announces Director Resignation
4. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
7. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
8. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
9. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
10. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
(Date:1/18/2017)... NJ (PRWEB) , ... January 18, 2017 , ... ... care communications company, launched a new website for its Center for Biosimilars, announced ... will include the latest developments in the field of biosimilars through thought leader ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... gum disease to enamel erosion, and those dental problems can increase the risk ... Health, many pregnant women are failing to get the dental care they need. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress ... dentists to choose the best drug option for each patient. Dentists have several general ... better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Iowa , Jan. 18, 2017   ... that subsidiary Caretta Therapeutics plans, in the second ... Venodol, a topical roll-on intended to provide relief ... opioid and steroidal analgesics. It was developed under ... to commercialize products derived from snake venom. ...
(Date:1/18/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, announces dosing the first patient ... 2 acne rosacea study. DMT210 is a topical ... in the skin responsible for the inflammation and ... This clinical trial, DMT210-003, is a 12-week, Phase ...
(Date:1/18/2017)... Jan. 17, 2017  With an annual growth ranging from 6% to 10%, ... SEA (Jakarta International Expo, March 22-24, 2017) serves the industry by fostering the ... CPhI SEA 2017? Investment Forum ASEAN -- ... Richer conference content Enhanced business matchmaking program ... ...
Breaking Medicine Technology: